The condition of a co-infected patient can be even worse. There is good news about the treatment of hepatitis D. Vir Biotechnology is advancing its combination treatment in hepatitis B and D, but it is pausing further development in hepatitis B while it is looking for a suitable partner.
In 2024, Vir arrived at a liver disease conference with data from a Phase 2 trial showing that two combination regimens using its drugs for bevibart and alebsiran were able to reduce hepatitis B surface antigens. The company planned to continue the trial up to the 24-week stage to evaluate whether its cocktail therapy could serve as a functional cure for chronic hepatitis B patients. According to the biotech's fourth-quarter earnings release, Vir Biotechnology still expects this data in the second quarter of the year.
I think this is a great news; it's time to congratulate! Best wishes to Vir Biotechnology for moving forward without delay. He then added, We are poised for significant progress with the start of our Phase 3 registration program in chronic hepatitis delta and further clinical progress of our dual-masked T-cell engagers in solid tumours. Please watch full video to know more about the details.
